The global Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Postmenopausal osteoporosis refers to reduced bone mass and density, which increases the risk of fractures due to age-related decline in estrogen levels after menopause. Osteoporosis medications aid in maintaining bone density and preventing fractures.
Market key trends:
One of the key trends in the postmenopausal osteoporosis market is the increased usage of advanced drugs for preventing osteoporosis and treating postmenopausal women with established osteoporosis. For instance, Evenity, approved by the FDA in 2019, is a monoclonal antibody that targets a protein called sclerostin, which acts as a brake on bone formation. By blocking sclerostin, Evenity helps reduce the risk of fractures. It represents an innovative treatment option through a novel mechanism of action that selectively enhances bone formation at sites of high bone remodeling.
Strength: Postmenopausal osteoporosis market has a large patient pool due to increasing geriatric population globally. Advancements in treatment options such as monoclonal antibodies and anabolic drugs for postmenopausal osteoporosis have enhanced the efficacy of treatment.
Weakness: Stringent regulatory landscape and high costs associated with R&D and clinical trials of drugs hampers market growth. Adverse effects associated with long term usage of drugs also acts as a restraint.
Opportunity: Increasing awareness regarding osteoporosis treatment and diagnosis presents an opportunity for market growth. Evolving healthcare infrastructure in emerging nations provide scope for industry expansion.
Threats: Patent expiry of blockbuster drugs results in more generic drugs availability decreasing prices of branded drugs. Alternative treatment options such as supplements, exercise and lifestyle changes pose a threat to drug adoption.
Market size: The Global Postmenopausal Osteoporosis Market Size is expected to witness high growth, exhibiting CAGR of 4.4% over the forecast period, due to increasing geriatric population globally prone to osteoporosis.
Regional analysis: North America commanded the major share of the market in 2023 owing to advanced healthcare infrastructure and increasing healthcare spending. Asia Pacific is estimated to exhibit fastest growth rate during the forecast period due to evolving healthcare facilities, large patient pool and health awareness programs in the region.
Key players: Key players operating in the postmenopausal osteoporosis market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc. Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it